17 citations
,
August 2002 in “AIDS” This study observed that patients undergoing indinavir/ritonavir therapy for HIV-1 frequently experienced reversible alopecia, likely due to retinoid-like effects, but these were independent of other retinoid-like skin manifestations.
7 citations
,
June 2007 in “AIDS” This report describes the first case of hair loss in a patient on ritonavir-boosted atazanavir therapy for HIV, with hair regrowth following a switch to a non-protease inhibitor regimen.
5 citations
,
July 2007 in “PubMed” This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.
1 citations
,
October 2023 in “Journal of the Endocrine Society” In this case report, researchers highlight a 57-year-old HIV patient on ritonavir who developed Cushing’s syndrome from over-the-counter intranasal fluticasone, underscoring the risks of drug interactions and the importance of counseling patients about potential steroid ingredients in OTC products.
1 citations
,
May 2021 in “Journal of the Endocrine Society” This case report describes a woman with HIV who developed iatrogenic Cushing syndrome and adrenal insufficiency due to the interaction between fluticasone and ritonavir, highlighting the need for careful management of corticosteroid use in patients on protease inhibitors.